-+ 0.00%
-+ 0.00%
-+ 0.00%
Xiansheng Pharmaceutical (02096): SIM0712 (STAT6) was issued a drug clinical trial approval notice by the State Drug Administration
Share
Listen to the news

Zhitong Finance App News, Xiansheng Pharmaceutical (02096) announced that SIM0712, an oral small molecule degradant with target signal transduction and transcription initiation factor 6 (“STAT6”) independently developed by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration to carry out clinical trials for the treatment of atopic dermatitis.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending